Loader
Close

FET INNOVATION LAUNCHPAD PROJECT.

FET INNOVATION LAUNCHPAD PROJECT.

THE PRISMA PROJECT.

Peristaltic multistage micro-mechanical pump for next generation diabetes management.

The FET Innovation LAUNCHPAD PRISMA is an EU-funded project for the development of a new micro-pump, to be integrated into a transdermal patch, for the delivery of three hormones by micro-needles.

This project is born from the previous FET Open project BioWings, during which the thin and biocompatible film cerium oxide actuating electrostriction membrane is developing, for the application in silicon-based MEMS (Micro-Electro-Mechanical-System) and microfluidic systems.
The objective is to exploit the BioWings results to design a novel MEMS that works as a multistage peristaltic pump.

THE PRISMA PROJECT.

Peristaltic multistage micro-mechanical pump for next generation diabetes management.

The FET Innovation LAUNCHPAD PRISMA is an EU-funded project for the development of a new micro-pump, to be integrated into a transdermal patch, for the delivery of three hormones by micro-needles.

This project is born from the previous FET Open project BioWings, during which the thin and biocompatible film cerium oxide actuating electrostriction membrane is developing, for the application in silicon-based MEMS (Micro-Electro-Mechanical-System) and microfluidic systems.
The objective is to exploit the BioWings results to design a novel MEMS that works as a multistage peristaltic pump.

THE NEED.

Diabetes is a major global problem, directly responsible for more than 1.6 million deaths, and other 2.2 million due to high blood glucose levels. It is estimated that around 422 million people are affected by this disease globally, with an incidence of about 8.5% of the adult population.

 

Diabetes treatment starts from a change in lifestyle and always entails a life-long insulin administration. This is not a trivial task for diabetic patients, as the amount of insulin to deliver is patient specific, and has a highly dynamic evolution over time, for example due to meal composition, sleep cycles and physical activity. New Closed-loop Artificial Pancreas are currently being studied and promise an agile solution to the difficult challenge of insulin treatment for patients with type 1 diabetes management. However, the technical limitations of current electromechanical micro-pumps do not allow a simultaneously multiple hormones delivery, with small dimensions and the adequate performances.

THE NEED.

Diabetes is a major global problem, directly responsible for more than 1.6 million deaths, and other 2.2 million due to high blood glucose levels. It is estimated that around 422 million people are affected by this disease globally, with an incidence of about 8.5% of the adult population.

Diabetes treatment starts from a change in lifestyle and always entails a life-long insulin administration. This is not a trivial task for diabetic patients, as the amount of insulin to deliver is patient specific, and has a highly dynamic evolution over time, for example due to meal composition, sleep cycles and physical activity. New Closed-loop Artificial Pancreas are currently being studied and promise an agile solution to the difficult challenge of insulin treatment for patients with type 1 diabetes management. However, the technical limitations of current electromechanical micro-pumps do not allow a simultaneously multiple hormones delivery, with small dimensions and the adequate performances.

THE CHALLENGE.

The challenge is to have a pump system that is small enough not to be visible under the clothes of the user, smart enough to be able to administer the correct injections at the appropriate times and precise enough to yield a fine control as well as a correct mixing ratio of particularly the insulin and amylin.

 

In short, the achievement of a multi-hormone closed-loop system requires two innovations:

    • A transdermal hormone delivery device, which replaces state-of-the-art invasive insulin delivery systems, and administers the correct amount of insulin, glucagon, and amylin;
    • A micropump able to precisely mix the right amount of hormones through a smart patch with microneedles.
Schematic representation of the Prisma smart patch
Schematic representation of the Prisma smart patch

THE CHALLENGE.

The challenge is to have a pump system that is small enough not to be visible under the clothes of the user, smart enough to be able to administer the correct injections at the appropriate times and precise enough to yield a fine control as well as a correct mixing ratio of particularly the insulin and amylin.

In short, the achievement of a multi-hormone closed-loop system requires two innovations:

    • A transdermal hormone delivery device, which replaces state-of-the-art invasive insulin delivery systems, and administers the correct amount of insulin, glucagon, and amylin;
    • A micropump able to precisely mix the right amount of hormones through a smart patch with microneedles.
Schematic representation of the Prisma smart patch
Schematic representation of the Prisma smart patch

LEARN MORE.

INNOVATION AND LINK WITH THE BIOWINGS FET-OPEN PROJECT.

The research carried out in the ongoing FET-OPEN project “BioWings” has realized a thin film cerium oxide actuating electrostrictor membrane which is biocompatible and can be fully integrated with silicon-based MEMS (Micro-Electro-Mechanical-System) and microfluidic systems.
The idea behind the PRISMA FET Innovation Launchpad project is to exploit the properties of the electrostrictor membrane developed in the BioWings project to design and fabricate a novel MEMS that works as a multistage peristaltic pump.

With PRISMA we aim to validate the feasibility, both from a technical and from the business point of view, of a new infusion device, which integrates this micro-pump to deliver three hormones in reduced dimensions.

The PRISMA core innovation is a flat smart patch containing MEMS peristaltic micropumps which enable transdermal delivery of a triple-hormone solution for diabetes patients. The proposed closed-loop solution consists of:

      1. The smart patch containing the MEMS micropump, a battery, a microprocessor that controls its activation and the microneedles system for the transdermal delivery of the hormones;
      2. A glucose monitoring sensor;
      3. A mobile app that processes the glucose level in real time, converts it into injection volumes of the three hormones and submits instructions wirelessly to the microprocessor.

The PRISMA solution has the potential to provide ideal regulation of the blood glucose concentration and overcome the limitations of standard solutions such as pen-based technology, as well as of standard pu

mping patch systems. These limitations include slow pumping rate, pump size, difficulty in working with highly viscous fluids and the need for multi-pump modules for multiple hormones therapy.

THE PROJECT CONSORTIUM.

The project is coordinated by Day One, a Startup Studio specialised in launching and supporting high tech startups together with European researchers, which is also Exploitation Manager in the BioWings project. Day One’s mission is to transfer to the industrial world the most promising technologies developed by research centers, universities, and startups through a continuous interaction with industrial end-users.

Day One is currently following around 100 new technologies, has accelerated 80 startups raising more than 70M€ of public and investor funding, and has a staff of 15 people, including experienced project managers, as well as technology and market specialists

Day One will support CeOx, a spin-off company launched in the frame of the BioWings project to commercialise the IP generated by the project coordinator DTU.

 

CEOX is a newly established startup founded in March 2019, and based in Copenhagen.

The company was founded by two employees at the Technical University of Denmark, to focus on the commercialization of the research activities on electrostrictive materials. The start-up is a result of the EU FET-open project BioWings.

CEOX vision is to develop non-toxic and bio-compatible microelectromechanical systems (MEMS) integrated with electronic control circuitry on silicon. The aim is to produce all-in-one products for medical applications such as health sensing and smart drug delivery.

Day One logo


PRISMA GOALS.

Project partners CeOx and Day One will carry out the activities planned for this FET Innovation Launchpad project, which aims at validating both the technical and business feasibility of the PRISMA device, to pave for its development, clinical validation and commercialisation by 2025.

The project plan is organized in 4 sequential goals:

user-centered-design.icon
Goal 1
User Centered Design:

A User Centered Design of the Prisma solution: the Consortium involves stakeholders such as physicians experts in diabetes treatment and patients.

techfeasability
Goal 2
Technical feasibility:

Once we collect the desired functionalities and requirements, a technical feasibility study will be carried out for each core component of the Prisma solution.

business-feas
Goal 3
IP feasibility:

An initial freedom to operate analysis will be carried out to highlight possible third party’s patents that could hinder the product development and its further commercialization.

intellectual-property
Goal 4
Business feasibility:

The viability of the solution will be assessed through a preliminary Health Technology Assessment, and a business feasibility study will allow us to quantify the business opportunity.

CONTACTS.

Paolo de Stefanis

Day One

Project Coordinator

Lorenzo Sbizzera

Day One

Business Strategy

Simone Santucci

CeOx

Technical Manager

Paolo de Stefanis

Day One

 

Project Coordinator

 

Lorenzo Sbizzera

Day One

 

Business Strategy

 

Simone Santucci

CeOx

 

Technical Manager

 

EUROPEAN-UNION_low

PRISMA

This project has received funding from the European Union’s Horizon 2020 research and innovation programme.

Grant agreement ID: 101034822

More information here.